Paving the way to precision medicine in multiple myeloma

Expert Rev Hematol. 2021 Apr;14(4):323-327. doi: 10.1080/17474086.2021.1905515. Epub 2021 Apr 12.

Shafqat Inam¹, Jeremy A Ross², Cyrille Touzeau^{3

4}, Philippe Moreau⁵, Shaji K Kumar⁶, Simon J Harrison^{7

8}

¹ Clinical haematology, Peter MacCallum Cancer Centre, Victorian Comprehensive Cancer Centre, Melbourne, Australia.
² Precision Medicine, Oncology, AbbVie, North Chicago, IL, USA.
³ Service D'hématologie Clinique, Hotel Dieu, Nantes, France.
⁴ CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France.
⁵ Department of Hematology, University Hospital, Nantes, France.
⁶ Division of Hematology, Mayo Clinic, Rochester, MN, USA.
⁷ Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.
⁸ Sir Peter MacCallum Department of Oncology, Melbourne University, Melbourne, Australia.

No abstract available

Keywords: BCL2; Venetoclax; apoptosis; multiple myeloma; precision medicine; targeted therapy.

Publication types